AI Verdict
ENOV has stronger fundamentals based on our AI analysis.
ENTA vs ENOV Fundamental Comparison
| Metric | ENTA | ENOV |
|---|---|---|
| Revenue | $18.6M | $2.2B |
| Net Income | $-11.9M | $-1.2B |
| Net Margin | -64.1% | -52.7% |
| ROE | -9.4% | -79.5% |
| ROA | -3.6% | -30.9% |
| Current Ratio | 4.44x | 2.02x |
| Debt/Equity | 0.02x | 0.87x |
| EPS | $-0.42 | $-20.75 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
ENTA vs ENOV: Frequently Asked Questions
Is ENTA or ENOV a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), ENOV has stronger fundamentals. ENTA is rated STRONG SELL (85% confidence) while ENOV is rated SELL (85% confidence). This is not investment advice.
How does ENTA compare to ENOV fundamentally?
ENANTA PHARMACEUTICALS INC has ROE of -9.4% vs Enovis CORP's -79.5%. Net margins are -64.1% vs -52.7% respectively.
Which stock pays higher dividends, ENTA or ENOV?
ENTA has a dividend yield of N/A or no dividend while ENOV has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in ENTA or ENOV for long term?
For long-term investing, consider that ENTA has STRONG SELL rating with 85% confidence, while ENOV has SELL rating with 85% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about ENTA vs ENOV?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For ENTA vs ENOV, the AI consensus favors ENOV based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.